Back to All Peptides
💊

Orforglipron

Also known as: LY3502970, Oral GLP-1

The Future of Weight Loss - No Injections

Once-daily oral GLP-1 pill - no injections needed. The future of weight loss drugs. Currently in Phase 3 trials with ~15% weight loss in Phase 2.

Phase 3 Trials🔥 Weight Loss

How It Works

Orforglipronbinds toGLP-1/GIP ReceptortriggersMetabolic Enhancement123

Simple Explanation

Orforglipron is a small molecule (not a peptide) that activates the same GLP-1 receptors as semaglutide. Because it's not a peptide, it survives digestion and can be taken as a simple daily pill - no injections or special timing required.

Technical Details

Non-peptide small molecule GLP-1 receptor agonist. Unlike semaglutide (a peptide requiring special absorption enhancers), orforglipron is a small molecule that survives gastrointestinal transit intact. Activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve glucose homeostasis. Once-daily oral dosing with no food restrictions.

Pharmacokinetics & Storage

Half-Life

~25 hours (enables once-daily dosing)

Duration in circulation

Storage Requirements

Before use: Store at controlled room temperature 68-77°F (20-25°C)
After reconstitution: N/A - oral tablet formulation

As a small molecule oral drug (not a peptide), orforglipron has superior stability compared to injectable peptides. Standard pharmaceutical tablet storage applies.

Research Timeline: What Studies Have Observed

Based on clinical trial data and published research. Individual responses may vary significantly.

Week 1-4

Appetite reduction, GI adjustment

Week 4-12

Steady weight loss begins

Week 12-24

Significant weight loss (8-12%)

Week 24-36

Approaching maximum effect (~15%)

Benefits

  • Significant weight loss (~15% in Phase 2)
  • No injections required
  • No empty stomach/timing requirements
  • Daily pill convenience
  • Potentially lower cost than peptide GLP-1s

Potential Side Effects

Nausea

Common

Similar to injectable GLP-1s

moderate

Vomiting

Occasional

mild

Diarrhea

Common

mild

Decreased appetite

Very common

This is kind of the point

mild

Research Highlights

Phase 2 Obesity Trial (2023)

14.7% weight loss at 36 weeks with once-daily oral dosing

View Study

Type 2 Diabetes Study (2023)

Significant A1C reduction and weight loss in diabetic patients

View Study

ACHIEVE Phase 3 Program (2024)

Multiple Phase 3 trials ongoing evaluating efficacy and safety for obesity treatment

View Study

Frequently Asked Questions

How is orforglipron different from Rybelsus (oral semaglutide)?
Rybelsus is still a peptide requiring empty stomach dosing and absorption enhancers. Orforglipron is a small molecule - take it anytime with or without food. Much simpler and potentially cheaper to manufacture.
When will orforglipron be available?
Phase 3 trials are ongoing with Eli Lilly. If successful, FDA approval could come in 2025-2026. It would be a game-changer for oral weight loss medication.
Is orforglipron as effective as injectable semaglutide?
Phase 2 showed ~15% weight loss which is comparable to injectable GLP-1s. Phase 3 will confirm efficacy. The convenience of no injections could improve adherence and real-world results.
Why is an oral GLP-1 such a big deal?
Injectable GLP-1s require weekly shots, cold storage, and medical supplies. A daily pill is dramatically more convenient and could make GLP-1 therapy accessible to many more people who avoid injections.

Who Is It For

  • Those who want GLP-1 benefits without injections
  • People with needle phobia
  • Those seeking convenience over injectable options
  • Future patients once FDA approved

Who Should Avoid

  • Those needing treatment now (not yet approved)
  • History of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Severe GI conditions

Research Dosing Protocols

Common Research Protocol

Up to 45mg once daily (Phase 3 doses)

Administration Frequency (per studies)

Once daily, any time, with or without food

Delivery Methods

oral

Available Forms

  • • Oral tablet

💡 Not yet approved - Phase 3 trials ongoing. Dose titration likely required.

⚠️ Not Medical Advice: Dosing information is compiled from published research and clinical studies for educational purposes only. This is not a recommendation. All peptide research should be conducted by qualified professionals in controlled research environments. Consult a healthcare provider before considering any protocol.

Where to Buy

Looking for quality Orforglipron? Check our vetted suppliers.

View Trusted Suppliers

Related Peptides

🔥Semaglutide

If you've heard of Ozempic, you've heard of semaglutide. Originally for Type 2 diabetes, it became a phenomenon when people started losing 15-20% of their body weight.

🔥Tirzepatide

Tirzepatide outperforms semaglutide in head-to-head trials. As a dual GLP-1/GIP agonist, people are losing 20-25% body weight.

🔥Retatrutide

Triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24% weight loss with emerging anti-cancer data.

⚠️ Important Disclaimer

This information is for educational purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use by the FDA. Always consult with a qualified healthcare provider before starting any peptide protocol. PepGains does not sell peptides and is not responsible for how this information is used. All timeline and efficacy information is based on published research and clinical trials - individual results may vary significantly.